Seeking to address rising prescription drug costs, UnitedHealthcare (UNH) said Tuesday that it will pass along some rebates that the big insurer receives from drug makers, a move that may provide relief to a small portion of consumers, but was also criticized for failing to address the larger problem of rising medicine prices.
Starting next year, the insurer will redirect a majority of rebates for around 7.5 million people, and expects to reduce costs from just a few dollars to more than $1,000 for each prescription. However, the initiative will not include an estimated 18.6 million consumers who are covered by so-called self-insured plans, in which employers pay for health care benefits.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Assuming Mr hill is correct in this – “The problem with the model is the vast majority of rebates are generated by a small number of beneficiaries taking expensive brand and specialty drugs. ” – would that explain why the PBMs have gotten less attention until now? This really only took off with EpiPen and Heather Bresch, as I remember.